


CMA Recommendations on Vaccine Equity and Intellectual Property

<https://policybase.cma.ca/link/policy14476>

POLICY TYPE	Parliamentary submission
DATE	2022-05-13
TOPICS	Ethics and medical professionalism Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents



Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

<https://policybase.cma.ca/link/policy14443>

POLICY TYPE	Policy endorsement
DATE	2021-06-24
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents



Taking action on drug shortages during Covid-19 - open letter

<https://policybase.cma.ca/link/policy14261>

POLICY TYPE Parliamentary submission
DATE 2020-08-13
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents



Authorizing Cannabis for Medical Purposes

<https://policybase.cma.ca/link/policy11514>

POLICY TYPE	Policy document
LAST REVIEWED	2020-02-29
DATE	2015-02-28
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents

ASSOCIATION
MÉDICALE
CANADIENNE  CANADIAN
MEDICAL
ASSOCIATION **CMA POLICY**

Authorizing Cannabis for Medical Purposes

The legislation of cannabis for recreational purposes came into effect with the Cannabis Act in October 2018, and patients continue to have access to cannabis for therapeutic purposes. The Cannabis Regulations have replaced the Access to Cannabis for Medical Purposes Regulations. Patients can obtain cannabis for medical purposes when a physician or nurse practitioner provides a "medical document", authorizing its use, and determining the daily dried cannabis dose it goes.

With the authorization, patients have the choice whether to (a) buy directly from a federally licensed producer, (b) register with Health Canada to produce a limited amount for personal consumption, (c) designate someone to produce it for them, or (d) buy cannabis on provincial or territorial authorized retail outlets or online sales platforms, if above the legal age limit.

While acknowledging the unique requirements of patients suffering from a terminal illness or chronic disease for which conventional therapies have not been effective and for whom cannabis may provide relief, physicians remain concerned about the serious lack of clinical research, guidance and regulatory oversight for cannabis as a medical treatment. There is insufficient clinical information on safety and efficacy for most therapeutic claims. There is little information on oral therapeutic and food dosages and knowledge on interactions with medications. Besides the need for appropriate research, health practitioners would benefit from unbiased, accredited educational modules and decision support tools based on the best available evidence.

The Canadian Medical Association has consistently expressed concern with the role of gatekeeper that physicians have been called to take as a result of court decisions. Physicians should not feel obligated to authorize cannabis for medical purposes.

Physicians who choose to authorize cannabis for their patients must comply with their provincial or territorial regulatory Colleges' relevant guideline or policy. They should also be familiar with regulations and guidance, particularly:

- Health Canada's Information for Health Care Practitioners – Medical Use of Cannabis (Interim): Summary and Quick Start Sheet¹
- the Canadian Medical Protective Association's guidance²
- the College of Family Physicians of Canada's preliminary guidance Authorizing Dried Cannabis for Chronic Pain or Anxiety³, and
- the 5-year-old guideline for prescribing medical cannabis in its primary care, published in the Canadian Family Physician⁴


© 2020 Canadian Medical Association. All rights reserved. Reproduction of this document is permitted in whole or in part without any form of payment, provided copies of this policy have been printed. Permission is granted to translate this document.

Health Canada consultation on reducing youth access and appeal of vaping products

<https://policybase.cma.ca/link/policy14078>

POLICY TYPE	Response to consultation
DATE	2019-05-24
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents




Cannabis for Medical Purposes

<https://policybase.cma.ca/link/policy10045>

POLICY TYPE	Policy document
LAST REVIEWED	2019-03-03
DATE	2010-12-04
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




Medication use and seniors (Update 2017)

<https://policybase.cma.ca/link/policy10151>

POLICY TYPE	Policy document
LAST REVIEWED	2019-03-03
DATE	2011-05-28
REPLACES	Medication use and seniors
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

<https://policybase.cma.ca/link/policy10670>

POLICY TYPE	Policy document
LAST REVIEWED	2019-03-03
DATE	2012-12-08
TOPICS	Health information and e-health Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on edible cannabis, extracts & topicals

<https://policybase.cma.ca/link/policy14020>

POLICY TYPE	Response to consultation
DATE	2019-02-20
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents




Health Canada consultation on Canadian drugs and substances strategy

<https://policybase.cma.ca/link/policy14017>

POLICY TYPE	Response to consultation
DATE	2018-12-04
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Population health, health equity, public health

Documents




Implementation of National Pharmacare

<https://policybase.cma.ca/link/policy13933>

POLICY TYPE	Response to consultation
DATE	2018-10-02
TOPICS	Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on tobacco products regulations (plain and standardized appearance)

<https://policybase.cma.ca/link/policy13930>

POLICY TYPE	Response to consultation
DATE	2018-09-06
TOPICS	Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs

Documents



Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

<https://policybase.cma.ca/link/policy13931>

POLICY TYPE	Policy endorsement
DATE	2018-08-30
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on regulatory amendments regarding tramadol

<https://policybase.cma.ca/link/policy13927>

POLICY TYPE Response to consultation
DATE 2018-08-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents




Health Canada consultation on restriction of marketing and advertising of opioids

<https://policybase.cma.ca/link/policy13921>

POLICY TYPE	Response to consultation
DATE	2018-07-18
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents



Consultation on proposed front-of-package labelling

<https://policybase.cma.ca/link/policy13882>

POLICY TYPE	Response to consultation
DATE	2018-04-23
TOPICS	Health care and patient safety Pharmaceuticals, prescribing, cannabis, drugs

Documents




Bill C-45: The Cannabis Act

<https://policybase.cma.ca/link/policy13861>

POLICY TYPE	Parliamentary submission
DATE	2018-04-18
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents




CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers' Health Act and to make consequential amendments to other Acts

<https://policybase.cma.ca/link/policy13918>

POLICY TYPE	Parliamentary submission
DATE	2018-02-15
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs Health care and patient safety

Documents




Proposed approach to the regulation of cannabis

<https://policybase.cma.ca/link/policy13838>

POLICY TYPE	Response to consultation
DATE	2018-01-19
TOPICS	Pharmaceuticals, prescribing, cannabis, drugs

Documents



Excise duty framework for cannabis products

<https://policybase.cma.ca/link/policy13799>

POLICY TYPE Response to consultation
DATE 2017-12-07
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

